CRAIG E. METROKA, M.D., PH.D.; ANNE MOORE, M.D.; JOSEPH A. SONNABEND, M.B.; SUSANNA CUNNINGHAM-RUNDLES, PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Recently, danazol (Danocrine; Winthrop Laboratories, New York, New York) has been reported to decrease the need for transfusions of plasma products in persons with classic hemophilia and hemophilia B (Christmas disease) (1), to increase the platelet count in patients with autoimmune thrombocytopenic purpura (2), and to restore the T4/T8 ratio and lymphoproliferative responses to normal in patients with autoimmune thrombocytopenic purpura (3; FISCHL M. Personal communication.). These observations prompted us to examine the possibility that danazol might be able to improve T-cell function in patients with untreated Kaposi's sarcoma and persons who had clinically recovered from an
METROKA CE, MOORE A, SONNABEND JA, CUNNINGHAM-RUNDLES S. Risks with Danazol in the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1984;101:564–565. doi: 10.7326/0003-4819-101-4-564_2
Download citation file:
Published: Ann Intern Med. 1984;101(4):564-565.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use